Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Today we are bringing you part 1 of a 2-part podcast series on opportunities for biosimilars, specifically adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology.
The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute. The topics of conversation for today’s podcast include the provider and payer considerations for transitioning patients to biosimliars, challenges associated with biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen above or through one of these podcast services:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
Transforming Addiction Care: From Stigma to SupportSeptember 16th 2025
- Navigating the Alzheimer Disease Blood Test Revolution
September 9th 2025
- AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025
Managed Care Cast News Roundup: July 8, 2025July 8th 2025
